SCHEMBL7672276

SCHEMBL7672276

COc1ccc2nc(SC)[nH]c2c1

nearest known ligand 0.70

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2E1 P05181 16/20 0.70
CYP2C8 P10632 16/20 0.70
CYP2D6 P10635 16/20 0.70
CYP2C9 P11712 16/20 0.70
CYP2B6 P20813 16/20 0.70
CYP2C19 P33261 16/20 0.70
CYP1A2 P05177 15/20 0.70
CYP3A4 P08684 15/20 0.70
BRS3 P32247 1/20 0.63
HPGD P15428 2/20 0.61
SMN1; SMN2 Q16637 2/20 0.61
ALDH1A1 P00352 2/20 0.61
LMNA P02545 1/20 0.60
KDM4E B2RXH2 1/20 0.59
NPC1 O15118 1/20 0.59
TP53 P04637 1/20 0.59
TSHR P16473 1/20 0.59
NFKB1 P19838 1/20 0.59
RAB9A P51151 1/20 0.59
NFKB2 Q00653 1/20 0.59

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17153978 0.88 CYP2E1 (0.72) CYP2E1CYP2C8CYP2D6CYP2C9CYP2B6
SCHEMBL1101910 0.87 CYP2C19 (0.54) CYP2E1CYP2C8CYP2D6CYP2C9CYP2B6
SCHEMBL14304388 0.80 CYP2E1 (0.90) CYP2E1CYP2C8CYP2D6CYP2C9CYP2B6
SCHEMBL20982659 0.78 NPC1 (0.85) HPGDSMN1; SMN2ALDH1A1LMNAKDM4E
SCHEMBL29439014 0.77 KDM4E (0.61) CYP2E1CYP2C8CYP2D6CYP2C9CYP2B6
SCHEMBL4371528 0.77 KDM4E (0.61) CYP2E1CYP2C8CYP2D6CYP2C9CYP2B6
SCHEMBL4597364 0.77 ALDH1A1 (0.67) CYP2E1CYP2C8CYP2D6CYP2C9CYP2B6
SCHEMBL8768283 0.77 LMNA (0.97) CYP2E1CYP2C8CYP2D6CYP2C9CYP2B6
SCHEMBL4650010 0.77 CYP2E1 (1.00) CYP2E1CYP2C8CYP2D6CYP2C9CYP2B6
SCHEMBL10220063 0.77 CYP2E1 (0.61) CYP2E1CYP2C8CYP2D6CYP2C9CYP2B6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-110573605-B Slow rhizobium monooxygenase and application thereof in preparation of chiral sulfoxide 华东理工大学 2021-11-19 CN disclosed
US-10787651-B2 Bradyrhizobium monooxygenase and use thereof for preparation of chiral sulfoxide JIANGSU AOSAIKANG PHARMACEUTICAL CO., LTD. (CN) 2020-09-29 US disclosed
US-20200140830-A1 BRADYRHIZOBIUM MONOOXYGENASE AND USE THEREOF FOR PREPARATION OF CHIRAL SULFOXIDE JIANGSU AOSAIKANG PHARMACEUTICAL CO., LTD. (CN) 2020-05-07 US disclosed
CN-110573605-A Slow rhizobium monooxygenase and application thereof in preparation of chiral sulfoxide 华东理工大学 2019-12-13 CN disclosed
US-20170326104-A1 IRE-1ALPHA INHIBITORS FOSUN ORINOVE PHARMATECH, INC. (CN) 2017-11-16 US disclosed
US-20110245231-A1 ACTIVE SUBSTANCE AND PHARMACEUTICAL COMPOSITION FOR TREATING ALCOHOL DEPENDENCE, AND A METHOD FOR OBTAINING AND THE USE OF SAID ACTIVE SUBSTANCE ALLA CHEM, LLC (US) 2011-10-06 US disclosed
US-6350876-B2 REACTING SULFONYL CYANIDE DERIVATIVE WITH ALPHA,BETA-UNSAT-URATED CARBONYL COMPOUND; ORGANOLITHIUM COMPOUND; STARTING MATERIAL/INTERMEDIATE FOR DRUG SYNTHESIS (ANTI-PARKINSON'S DRUG LAZABEMIDE) AND AGRICULTURAL CHEMICALS (PESTICIDES) KURARAY CO., LTD. (JP) 2002-02-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170326104-A1 IRE-1ALPHA INHIBITORS ERN1, XBP1, ERN2 CYP2E1 1761/4885CYP2C8 3212/4885CYP2D6 2832/4885
US-20110245231-A1 ACTIVE SUBSTANCE AND PHARMACEUTICAL COMPOSITION FOR TREATING ALCOHOL DEPENDENCE, AND A METHOD FOR OBTAINING AND THE USE OF SAID ACTIVE SUBSTANCE ADH1C, ADH1A, ADH5 CYP2E1 10/4885CYP2C8 138/4885CYP2D6 111/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.